Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause

ClinicalTrials.gov ID: NCT06112756

Public ClinicalTrials.gov record NCT06112756. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause. Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life. The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances. The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo. For this, the researchers will analyze * change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment * change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment * change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment. The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks. Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned. During the study, the doctors and their study team will: * take blood and urine samples * do physical examinations * check vital signs * do sleep tests * use an electronic hand-held device to record sleep quality and hot flashes at home An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

Study identification

NCT ID
NCT06112756
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bayer
Industry
Enrollment
110 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
40 Years to 65 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 8, 2023 (Actual)
Primary completion
Aug 22, 2024 (Actual)
Completion
Nov 7, 2024 (Actual)
Last update posted
Nov 10, 2025

2023 – 2024

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
20
Facility City State ZIP Site status
Preferred Research Partners Little Port Walter Alaska 72211 —
MomDoc Women's Health Research | Scottsdale, AZ Scottsdale Arizona 85251 —
Diagnamics | Encinitas, CA Encinitas California 92024 —
SDS Clinical Trials Inc Santa Ana California 92705 —
Pacific Clinical Research Management Group LLC Upland California 91786 —
Helix Biomedics LLC | Boynton Beach, FL Boynton Beach Florida 33435 —
Sweet Hope Research Specialty, Inc. - Hialeah Hialeah Florida 33016 —
PharmaDev Clinical Research Institute, LLC Miami Florida 33176 —
Segal Trials - Women's Health & General Medicine Research Site North Miami Florida 33161 —
Palm Beach Research center West Palm Beach Florida 33409 —
Sleep Practitioners, LLC Macon Georgia 31210 —
SleepCare Research Institute Inc Stockbridge Georgia 30281 —
Brengle Family Medicine Indianapolis Indiana 46260 —
Revive Research Institute, Inc. - Women's Health Dearborn Heights Michigan 48127 —
Essential Women's Health Associates Las Vegas Nevada 89113 —
Clinilabs Drug Development Corporation-Feasibility Eatontown New Jersey 07724 —
CTI Clinical Research Center Cincinnati Ohio 45212 —
Intrepid Research, LLC. Cincinnati Ohio 45245 —
Bogan Sleep Consultants, LLC Columbia South Carolina 29201 —
FutureSearch Trials of Neurology LP Austin Texas 78731 —
Sleep Therapy and Research Center | Medical Center Drive Office San Antonio Texas 78229 —
Road Runner Research, Ltd. San Antonio Texas 78249 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06112756, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 10, 2025 · Synced Nov 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06112756 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →